A self-setting TTCP-DCPD apatite cement for release of vancomycin.
Vancomycin (VCM), a methiciline-cefem resistant Staphylococcus aureus (MRSA)-specific antibiotic, was incorporated in a self-setting tetracalcium phosphate (TTCP)-dicalcium phosphate dihydrate (DCPD) apatite cement that hardened isothermally into a hydroxyapatite (HAP) phase with crystallinity similar to that of host bone. Effective release of VCM into PBS lasted for 2 weeks from cements containing 1% VCM and for longer than 9 weeks from cements containing 5% VCM. The rate of release of VCM differed between cements with different crystallinities as well as between the two dissolution media, PBS and simulated body fluid. Mean concentration of VCM in the bone marrow tissue released from cements containing 5% VCM was 20 times the minimum inhibitory concentration 3 weeks after implantation in bone. Direct contact with new bone was observed with the cements containing 1% VCM. Slow delivery of VCM from a self-setting TTCP-DCPD apatite cement with low crystallinity could be used to treat MRSA osteomyelitis.
Hamanishi
C
C
Department of Orthopaedic Surgery, Kinki University School of Medicine, Osaka, Japan.
Kitamoto
K
K
Tanaka
S
S
Otsuka
M
M
Doi
Y
Y
Kitahashi
T
T
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D001843:Bone Cements; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D002130:Calcium Phosphates; D004577:Electron Probe Microanalysis; D011817:Rabbits; D012995:Solubility; D013977:Tibia / Q000166:cytology / Q000187:drug effects; D014640:Vancomycin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001843:Bone Cements; D002130:Calcium Phosphates; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D014640:Vancomycin; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous